Search

Author/Creator Hisahara, Shin

12. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Issue 7 (July 2021)

Authors:
Howard, James F; Bril, Vera; Vu, Tuan; Karam, Chafic; Peric, Stojan; Margania, Temur; Murai, Hiroyuki; Bilinska, Malgorzata; Shakarishvili, Roman; Smilowski, Marek; Guglietta, Antonio; Ulrichts, Peter; Vangeneugden, Tony; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato; De Bleeker, Jan;...
Journal:
Lancet neurology
Issue:
Volume 20:Issue 7(2021)
Page Start:
526
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

13. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Issue 7 (July 2021)

Authors:
Howard, James F; Bril, Vera; Vu, Tuan; Karam, Chafic; Peric, Stojan; Margania, Temur; Murai, Hiroyuki; Bilinska, Malgorzata; Shakarishvili, Roman; Smilowski, Marek; Guglietta, Antonio; Ulrichts, Peter; Vangeneugden, Tony; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato; De Bleecker, Jan...
Journal:
Lancet neurology
Issue:
Volume 20:Issue 7(2021)
Page Start:
526
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15. Ubiquitin-dependent rapid degradation conceals a cell-protective function of cytoplasmic SIRT3 against oxidative stress. (29th October 2021)

Authors:
Hayashi, Takashi; Matsushita, Takashi; Hisahara, Shin; Iwahara, Naotoshi; Kuno, Atsushi; Kunimoto, Risa; Hosoda, Ryusuke; Tanno, Masaya; Shimohama, Shun; Horio, Yoshiyuki
Journal:
Journal of biochemistry
Issue:
Volume 171:Number 2(2022)
Page Start:
201
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗